The Role of Private Equity in Life Sciences
In a roundtable published in this journal a year ago, there was a clear consensus that the R&D function in big pharma was inefficient and in need of major restructuring, possibly through increased investments by venture capital and private equity firms. In this discussion, an accomplished group of industry practitioners begins by looking at the prospects for both venture capital and private equity to play meaningful roles in financing early- and mid-stage drug development. In so doing, they explore questions like the following: Copyright Copyright (c) 2010 Morgan Stanley.
Year of publication: |
2010
|
---|---|
Authors: | Greene, Jeff ; Purcell, Dennis ; Edelman, Brian ; Giordano, Doug ; Ruback, Richard ; Mihas, Dean ; Opler, Tim ; Cahill, Tom ; Giovannetti, Glen |
Published in: |
Journal of Applied Corporate Finance. - Morgan Stanley, ISSN 1078-1196. - Vol. 22.2010, 2, p. 8-35
|
Publisher: |
Morgan Stanley |
Saved in:
freely available
Saved in favorites
Similar items by person
-
The Role of Private Equity in Life Sciences
Greene, Jeff, (2010)
-
The role of private equity in life sciences
Greene, Jeff, (2010)
-
Ernst & Young LLP roundtable on activist investors and their implications for corporate managers
Greene, Jeff, (2015)
- More ...